Practices & Lifestyle
Pyrilutamide (KX-826)
As of mid-2026, Kintor reports that the pivotal Phase III stage in China met its primary endpoint with statistically significant and clinically meaningful efficacy in male AGA; a 52-week long-term safety Phase III also met endpoint. US Phase II positive. NDA planned in China.
Topical RU58841
RU58841 (also called PSK-3841) is a non-steroidal topical antiandrogen developed by Roussel Uclaf (later Sanofi) in the late 1980s and 1990s as a topical treatment for androgenetic alopecia (AGA, male and female pattern hair loss). It is a pure…